US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evofem Biosciences, Inc.

0.0092

+0.00010.71%

Volume:69.51K

Turnover:636.27

Market Cap:1.04M

PE:0.00

High:0.0092

Open:0.0092

Low:0.0086

Close:0.0091

Loading ...

Overview Company News Filings

Evofem Biosciences Q1 Sales $845.00K Down From $3.60M YoY

Evofem Biosciences Reports Q1 2025 Net Income of $1M, Reversing $4.9M Loss YoY; EPS at $0.01

Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS

Evofem Biosciences Q1 Net Income USD 956 Thousand

THOMSON REUTERS

Evofem Biosciences Q1 Operating Expenses USD 518 Thousand

THOMSON REUTERS

Evofem Biosciences Expands Agreement with Pharma 1 Drug Store to Include New Product Packaging

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem announces license and supply agreement with Windtree Therapeutics

BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics

Evofem Expects Significant Reduction in Phexxi Manufacturing Cost Through Agreement With Windtree Therapeutics

THOMSON REUTERS

Evofem Biosciences Inc - Cost to Manufacture Phexxi Will Decrease by 55% - 60%

THOMSON REUTERS

Evofem Reports Fourth Consecutive Year of Net Sales Growth

THOMSON REUTERS

Press Release: Evofem Reports Fourth Consecutive Year of Net Sales Growth

BUZZ-Windtree Therapeutics rises on licensing deal for birth control vaginal gel

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EVFM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVFM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","market":"US","secType":"STK","nameCN":"Evofem Biosciences, Inc.","latestPrice":0.0092,"timestamp":1747425600000,"preClose":0.009135,"halted":0,"volume":69514,"delay":15,"floatShares":113354642,"shares":113356354,"eps":-19.076116,"marketStatus":"Pre-Mkt","change":0.000065,"latestTime":"05-16 16:00:00 EDT Delay","open":0.0092,"high":0.0092,"low":0.00857,"amount":636.2687550000002,"amplitude":0.068966,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-19.076116,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747661400000},"marketStatusCode":1,"adr":0,"exchange":"PINK","adjPreClose":0.0092,"volumeRatio":0.3876416837338557},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVFM\",,,,,undefined,":{"symbol":"EVFM","floatShares":113354642,"roa":"-26.70%","roe":"-387.27%","lyrEps":-23.631594,"volumeRatio":0.3876416837338557,"shares":113356354,"dividePrice":0,"high":0.0092,"amplitude":0.068966,"preClose":0.009135,"low":0.00857,"week52Low":0.006,"pbRate":"-0.01","psRate":"0.06","week52High":0.019,"institutionHeld":0,"latestPrice":0.0092,"eps":-19.076116,"divideRate":0,"volume":69514,"delay":15,"ttmEps":-19.076116,"open":0.0092,"prevYearClose":0.0099,"prevWeekClose":0.0092,"prevMonthClose":0.0088,"prevQuarterClose":0.0088,"fiveDayClose":0.0085,"twentyDayClose":0.009,"sixtyDayClose":0.009},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVFM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535957829","title":"Evofem Biosciences Q1 Sales $845.00K Down From $3.60M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535957829","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535957829?lang=en_us&edition=fundamental","pubTime":"2025-05-15 21:56","pubTimestamp":1747317418,"startTime":"0","endTime":"0","summary":"Evofem Biosciences (OTC:EVFM) reported $845.00 thousand in sales this quarter. This is a 76.55 percent decrease over sales of $3.60 million the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45438575/evofem-biosciences-q1-sales-845-00k-down-from-3-60m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM"],"gpt_icon":0},{"id":"2535593844","title":"Evofem Biosciences Reports Q1 2025 Net Income of $1M, Reversing $4.9M Loss YoY; EPS at $0.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2535593844","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535593844?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310360,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire  on May 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nNDL7KvD8h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVFM","ADTX","WINT"],"gpt_icon":0},{"id":"2535384482","title":"Evofem Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535384482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535384482?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nTUABCXFDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4584","BK4007"],"gpt_icon":0},{"id":"2535844846","title":"Evofem Biosciences Q1 Net Income USD 956 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2535844846","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535844846?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310342,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nPLXE0AEBA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","BK4584","BK4007"],"gpt_icon":0},{"id":"2535784484","title":"Evofem Biosciences Q1 Operating Expenses USD 518 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2535784484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535784484?lang=en_us&edition=fundamental","pubTime":"2025-05-15 19:59","pubTimestamp":1747310342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nPLXE0AEBA:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4584","EVFM","BK4007"],"gpt_icon":0},{"id":"2534516671","title":"Evofem Biosciences Expands Agreement with Pharma 1 Drug Store to Include New Product Packaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2534516671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534516671?lang=en_us&edition=fundamental","pubTime":"2025-05-09 04:08","pubTimestamp":1746734934,"startTime":"0","endTime":"0","summary":"Evofem Biosciences Inc. has announced an amendment to its Development and Supply Agreement with Pharma 1 Drug Store L.L.C., a limited liability company based in the United Arab Emirates. The amendment, signed on May 3, 2025, introduces a new 3-applicator package size of the Licensed Product, in addition to the existing 12-applicator package. This strategic move aims to enhance product offerings and meet diverse consumer needs. The full details of the amendment are available in the company's Current Report on Form 8-K.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDLB3GJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"gpt_icon":0},{"id":"2528719078","title":"Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™","url":"https://stock-news.laohu8.com/highlight/detail?id=2528719078","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528719078?lang=en_us&edition=fundamental","pubTime":"2025-04-17 20:15","pubTimestamp":1744892100,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., April 17, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune, Inc. .Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Officer of Adimune, Inc.Event Details:Title: Aditxt Weekly UpdateDate: Friday, May 2, 2025Time: 11:30 a.m. ETLocation: Virtual Registration: Click here to register. ADI-100 is designed to work through precision immune reprogramming, downregulating pro-inflammatory cytokines while upregulating anti-inflammatory cytokine","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dr-charles-howe-mayo-clinic-121500791.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4007","LU0162691827.USD","BK4504","BK4588","LU1267930490.SGD","EVFM","BAX","ADTX","LU0211328371.USD","LU0006061336.USD","BK4082","LU0310799852.SGD","LU1303367103.USD","LU0072461881.USD","BK4584","LU2098885051.SGD","LU0211327993.USD","BK4139"],"gpt_icon":0},{"id":"2527948216","title":"Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527948216","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527948216?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:15","pubTimestamp":1744805700,"startTime":"0","endTime":"0","summary":"Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic Endometriosis Test, a potential non-invasive approach to surgical diagnosis for endometriosis. MOUNTAIN VIEW, Calif., April 16, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. , has received Institutional Review Board  approval from WCG Clinical to initiate a prospective clinical study evaluating the Mitomic Endometriosis Test , a novel blood-based diagnostic designed to aid in the early detection of endometriosis.Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests. This diagnostic delay can lead to chronic pain, infertility and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-pearsanta-receives-irb-121500094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1496350502.SGD","LU1989771016.USD","MET","BK4007","BK4585","EVFM","LU1291159041.SGD","LU1989772923.USD","BK4584","BK4162","LU1989772840.SGD","ADTX","BK4139","BK4588"],"gpt_icon":0},{"id":"2527418139","title":"Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2527418139","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527418139?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"WARRINGTON, Pa., April  15, 2025  (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage inno","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3061660/0/en/Windtree-Therapeutics-Reports-Year-End-2024-Financial-Results-and-Provides-Key-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","LENZ","BK4007","EVFM","BK4139"],"gpt_icon":0},{"id":"2527549911","title":"Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549911","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549911?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"MIAMI, April 15, 2025  -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025.The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/presenting-emerging-growth-conference-81-110000154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","CIA","BK4007","NQmain","OMEX","BK4583","GOVX","ASBP","UURAF","BK4213","BENF","BNZI",".IXIC","BK4023","SQQQ","MNQmain","SEVCF","SBC","BK4196","URG","USAW.SI","NVA.AU","BK4075","XXII","BK4077","QLD","BK4017","BK4139","NVA","NVAWW","PSQH","BK4124","ELRRF","BK4584","CLNN","PSQ","OPWEF","HGRAF","NVIW.SI","TQQQ","BK4135","QID","EVFM","CUAUF","BK4162","BIXT","BK4168","BK4137","USEG","USJW.SI"],"gpt_icon":1},{"id":"2527015710","title":"Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015710","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015710?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:15","pubTimestamp":1744632900,"startTime":"0","endTime":"0","summary":"Findings Further Support the Safety Profile and Immunomodulatory Effects of ADI-100, Adimune’s Lead Therapeutic Candidate for Autoimmune Diseases. The independent study, led by Dr. Sean Pittock and Dr. Charles Howe of the Mayo Clinic’s neuroimmunology team, confirmed that ADI-100 induces immune tolerance to glutamic acid decarboxylase —a key autoantigen implicated in multiple autoimmune conditions, including type 1 diabetes, stiff person syndrome, cerebellar ataxia, and autoimmune epilepsy.\"These results mark an important milestone not only for Adimune’s platform but also for Aditxt’s broader vision of transforming the way we approach autoimmune diseases,\" said Amro Albanna, co-founder and CEO of Aditxt. \"We believe that autoimmunity represents one of the most underserved and challenging areas of medicine. ADI-100’s potential ability to restore immune tolerance without broad immunosuppression is a meaningful step toward safer, more targeted treatments.\". Immune Modulation at the Cellul","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-subsidiary-adimune-announces-positive-121500858.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0162691827.USD","LU2098885051.SGD","AAN","EVFM","LU0072461881.USD","LU0211328371.USD","BK4504","LU0310799852.SGD","LU0006061336.USD","BK4588","LU0211327993.USD","BK4139","BK4585","BK4082","BK4178","ADTX","BAX","BK4007","BK4584","LU1267930490.SGD","LU1303367103.USD"],"gpt_icon":0},{"id":"2526657426","title":"Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2526657426","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526657426?lang=en_us&edition=fundamental","pubTime":"2025-04-11 20:15","pubTimestamp":1744373700,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., April 11, 2025----Aditxt, Inc.  , a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will provide key updates on recent events, including:. Aditxt’s recent notice from Nasdaq that it had regained compliance with Nasdaq’s minimum bid price requirement and is therefore in compliance with the Nasdaq Capital Market’s listing requirements. Event Details:Title: Aditxt Weekly UpdateDate: Friday, April 11, 2025Time: 11:30 a.m. ETLocation: Virtual Registration: Click here to register. Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to \"Make Promising Innovations Possible Together.\" The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aditxt-weekly-highlight-recent-events-121500595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","BK4139","ADTX","BK4588","EVFM","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","BK4584","BK4585","IE00BKPKM429.USD","BK4007"],"gpt_icon":0},{"id":"2522757405","title":"Upcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2522757405","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522757405?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:15","pubTimestamp":1743164100,"startTime":"0","endTime":"0","summary":"Event to feature Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt; Chris Mitton, President of Pearsanta; and Dr. Roger Giese, Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University. MOUNTAIN VIEW, Calif., March 28, 2025----Aditxt, Inc. , , a social innovation platform accelerating promising health innovations, announced that today’s Aditxt Weekly Update will focus on the recent acquisition of the CaSe Platform by its subsidiary, Pearsanta, Inc. . The proprietary technology is based on adductomics and is designed to assess early DNA changes that may lead to mutations associated with cancer and other illnesses. The discussion will explore the platform’s role in advancing Pearsanta’s mission to address cancer through early detection and prevention.Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/upcoming-aditxt-weekly-highlight-pearsanta-121500269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADTX","EVFM","BK4007","BK4584","BK4139"],"gpt_icon":0},{"id":"2522805388","title":"Evofem announces license and supply agreement with Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522805388","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522805388?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:55","pubTimestamp":1742993732,"startTime":"0","endTime":"0","summary":"Evofem Biosciences (EVFM) announced that it has entered into a License and Supply Agreement with Windtree Therapeutics (WINT), under which Windtree...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evofem-announces-license-and-supply-agreement-with-windtree-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","EVFM","WINT","BK4584"],"gpt_icon":0},{"id":"2522204808","title":"BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522204808","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522204808?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:49","pubTimestamp":1742993391,"startTime":"0","endTime":"0","summary":"BRIEF-Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree TherapeuticsMarch 26 (Reuters) - Evofem Biosciences Inc EVFM.PK:EVOFEM EXPECTS SIGNIFICANT REDUC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","EVFM","WINT","BK4007","BK4139"],"gpt_icon":1},{"id":"2522808543","title":"Evofem Expects Significant Reduction in Phexxi Manufacturing Cost Through Agreement With Windtree Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2522808543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522808543?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:47","pubTimestamp":1742993244,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WINT","BK4139","BK4584","EVFM","BK4007"],"gpt_icon":0},{"id":"2522085128","title":"Evofem Biosciences Inc - Cost to Manufacture Phexxi Will Decrease by 55% - 60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522085128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522085128?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:47","pubTimestamp":1742993244,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90XO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EVFM","WINT","BK4139","BK4584","BK4007"],"gpt_icon":0},{"id":"2521272803","title":"Evofem Reports Fourth Consecutive Year of Net Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2521272803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521272803?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:30","pubTimestamp":1742819405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA4ZTX7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADTX","BK4584","BK4007","EVFM","BK4139","WINT"],"gpt_icon":0},{"id":"2521009728","title":"Press Release: Evofem Reports Fourth Consecutive Year of Net Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2521009728","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521009728?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:30","pubTimestamp":1742819400,"startTime":"0","endTime":"0","summary":"-- 2024 Net Sales Increased 6% to $19.4 Million --. -- Total Operating Expense Reduced 27% from 2023 Levels,-- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and. 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch --. SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. , today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include:. 2) The Company diversified its revenue stream with the July 2024 acquisition of SOLOSEC  2g oral granules, the single-dose oral treatment for bacterial vaginosis and trichomoniasis. Evofem relaunched SOLOSEC in November 2024 through its dedicated U.S. women's health commercial team.-- Evofem, Aditxt, Inc. , and Merger Sub entered into the. \"Our revenue growth and improved loss from operations in 2024 testify to the strength and persistence of this company. Our products matter, our people are tenacious, and we continu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WINT","EVFM"],"gpt_icon":1},{"id":"2521460918","title":"BUZZ-Windtree Therapeutics rises on licensing deal for birth control vaginal gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2521460918","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521460918?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:20","pubTimestamp":1742494850,"startTime":"0","endTime":"0","summary":"BUZZ-Windtree Therapeutics rises on licensing deal for birth control vaginal gel** Shares of biotechnology firm Windtree Therapeutics WINT.O rise 27.8% to $2.16 in afternoon trading** WINT says it has entered into a licensing deal with Evofem Biosciences EVFM.PK for its birth control vaginal gel, Phexxi     ** WINT will serve as the sourcing partner to Evofem and aims to produce Phexxi at a cheaper cost ** Co says Evofem will maintain ownership of the asset and continue to commercialize Phexxi in the U.S. and internationally** Up to last close, WINT has fallen 99.4% in the past 12 months  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nL4N3Q31F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4139","EVFM","BK4007","WINT"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVFM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-11-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2023-08-14","symbol":"EVFM","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691985600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVFM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVFM\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVFM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVFM","date":"2022-08-05","current":-0.166395,"percent":0.950893,"low":-6.597859,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"high":-0.031142,"avg":-1.49806,"sd":1.032744,"marketCap":31769672},"quantilePoints":[{"date":"2020-05-22","current":-3.05897,"twenty":-2.282595,"median":-1.374379,"eighty":-0.967209,"marketCap":248116113},{"date":"2020-05-29","current":-3.347089,"twenty":-2.295536,"median":-1.374379,"eighty":-0.967209,"marketCap":271485767},{"date":"2020-06-05","current":-3.192132,"twenty":-2.340109,"median":-1.375692,"eighty":-0.967209,"marketCap":258917031},{"date":"2020-06-12","current":-2.813714,"twenty":-2.417973,"median":-1.380547,"eighty":-0.969916,"marketCap":228223193},{"date":"2020-06-19","current":-2.79431,"twenty":-2.467359,"median":-1.385578,"eighty":-0.970593,"marketCap":226649240},{"date":"2020-06-26","current":-2.804012,"twenty":-2.565679,"median":-1.393527,"eighty":-0.974828,"marketCap":227436217},{"date":"2020-07-02","current":-2.891334,"twenty":-2.705047,"median":-1.405552,"eighty":-0.975919,"marketCap":234519005},{"date":"2020-07-10","current":-2.988359,"twenty":-2.741698,"median":-1.410607,"eighty":-0.977097,"marketCap":242388771},{"date":"2020-07-17","current":-2.813714,"twenty":-2.798191,"median":-1.413949,"eighty":-0.978316,"marketCap":228223193},{"date":"2020-07-24","current":-2.842822,"twenty":-2.813714,"median":-1.442913,"eighty":-0.981662,"marketCap":230584123},{"date":"2020-07-31","current":-2.901037,"twenty":-2.817595,"median":-1.451503,"eighty":-0.984607,"marketCap":235305982},{"date":"2020-08-07","current":-2.422033,"twenty":-2.817595,"median":-1.463115,"eighty":-0.986068,"marketCap":238151237},{"date":"2020-08-14","current":-2.587359,"twenty":-2.813714,"median":-1.465468,"eighty":-0.987517,"marketCap":254407295},{"date":"2020-08-21","current":-2.521229,"twenty":-2.813714,"median":-1.476662,"eighty":-0.988581,"marketCap":247904872},{"date":"2020-08-28","current":-2.587359,"twenty":-2.807893,"median":-1.489827,"eighty":-0.990273,"marketCap":254407295},{"date":"2020-09-04","current":-2.884947,"twenty":-2.813714,"median":-1.498338,"eighty":-0.994499,"marketCap":283668198},{"date":"2020-09-11","current":-1.735928,"twenty":-2.813714,"median":-1.501322,"eighty":-0.997697,"marketCap":170688600},{"date":"2020-09-18","current":-2.008717,"twenty":-2.809833,"median":-1.509563,"eighty":-0.999374,"marketCap":197511094},{"date":"2020-09-25","current":-1.84339,"twenty":-2.804012,"median":-1.510164,"eighty":-1.000561,"marketCap":181255037},{"date":"2020-10-02","current":-2.116179,"twenty":-2.804012,"median":-1.525046,"eighty":-1.001911,"marketCap":208077532},{"date":"2020-10-09","current":-2.397234,"twenty":-2.804012,"median":-1.542965,"eighty":-1.001911,"marketCap":235712829},{"date":"2020-10-16","current":-2.364169,"twenty":-2.800131,"median":-1.54827,"eighty":-1.001911,"marketCap":232461617},{"date":"2020-10-23","current":-2.083114,"twenty":-2.79431,"median":-1.561817,"eighty":-1.001911,"marketCap":204826320},{"date":"2020-10-30","current":-1.959119,"twenty":-2.790429,"median":-1.571494,"eighty":-1.002218,"marketCap":192634277},{"date":"2020-11-06","current":-2.025249,"twenty":-2.781758,"median":-1.588912,"eighty":-1.003413,"marketCap":199136700},{"date":"2020-11-13","current":-1.555597,"twenty":-2.774179,"median":-1.602459,"eighty":-1.004884,"marketCap":178003826},{"date":"2020-11-20","current":-1.655041,"twenty":-2.763731,"median":-1.588912,"eighty":-1.007151,"marketCap":189383066},{"date":"2020-11-27","current":-1.626629,"twenty":-2.753559,"median":-1.609695,"eighty":-1.009743,"marketCap":186131854},{"date":"2020-12-04","current":-1.576906,"twenty":-2.745522,"median":-1.591113,"eighty":-1.010116,"marketCap":180442234},{"date":"2020-12-11","current":-1.527184,"twenty":-2.743329,"median":-1.573429,"eighty":-1.011438,"marketCap":174752614},{"date":"2020-12-18","current":-1.47391,"twenty":-2.736486,"median":-1.569803,"eighty":-1.012602,"marketCap":168656593},{"date":"2020-12-24","current":-1.676351,"twenty":-2.729051,"median":-1.570648,"eighty":-1.013448,"marketCap":191821474},{"date":"2020-12-31","current":-1.726073,"twenty":-2.720643,"median":-1.573429,"eighty":-1.014445,"marketCap":197511094},{"date":"2021-01-08","current":-1.797105,"twenty":-2.718666,"median":-1.575364,"eighty":-1.014684,"marketCap":205639123},{"date":"2021-01-15","current":-1.889446,"twenty":-2.71669,"median":-1.596786,"eighty":-1.016196,"marketCap":216205560},{"date":"2021-01-22","current":-1.995994,"twenty":-2.705047,"median":-1.609695,"eighty":-1.017121,"marketCap":228397603},{"date":"2021-01-29","current":-1.882343,"twenty":-2.685112,"median":-1.620009,"eighty":-1.018306,"marketCap":215392757},{"date":"2021-02-05","current":-2.450598,"twenty":-2.681055,"median":-1.620116,"eighty":-1.018566,"marketCap":280416986},{"date":"2021-02-11","current":-2.507423,"twenty":-2.672813,"median":-1.632445,"eighty":-1.021168,"marketCap":286919409},{"date":"2021-02-19","current":-3.366908,"twenty":-2.71669,"median":-1.651829,"eighty":-1.024811,"marketCap":385268555},{"date":"2021-02-26","current":-2.848376,"twenty":-2.745246,"median":-1.655041,"eighty":-1.029338,"marketCap":325933946},{"date":"2021-03-05","current":-1.867672,"twenty":-2.747677,"median":-1.663725,"eighty":-1.032121,"marketCap":265786535},{"date":"2021-03-12","current":-1.676293,"twenty":-2.745246,"median":-1.660162,"eighty":-1.035221,"marketCap":238551624},{"date":"2021-03-19","current":-1.588682,"twenty":-2.743329,"median":-1.655041,"eighty":-1.038349,"marketCap":226083769},{"date":"2021-03-26","current":-1.204757,"twenty":-2.736696,"median":-1.653841,"eighty":-1.038718,"marketCap":171447831},{"date":"2021-04-01","current":-1.233,"twenty":-2.727622,"median":-1.645078,"eighty":-1.04011,"marketCap":175467057},{"date":"2021-04-09","current":-1.240046,"twenty":-2.726572,"median":-1.626629,"eighty":-1.040946,"marketCap":176469726},{"date":"2021-04-16","current":-1.099132,"twenty":-2.71669,"median":-1.619767,"eighty":-1.04998,"marketCap":156416348},{"date":"2021-04-23","current":-1.070949,"twenty":-2.71669,"median":-1.605319,"eighty":-1.04998,"marketCap":152405672},{"date":"2021-04-30","current":-1.055056,"twenty":-2.697285,"median":-1.589897,"eighty":-1.040946,"marketCap":150143944},{"date":"2021-05-07","current":-0.881622,"twenty":-2.676997,"median":-1.577001,"eighty":-1.04011,"marketCap":125462747},{"date":"2021-05-14","current":-0.740987,"twenty":-2.670023,"median":-1.573429,"eighty":-1.033139,"marketCap":125459522},{"date":"2021-05-21","current":-0.773593,"twenty":-2.664959,"median":-1.570648,"eighty":-1.021948,"marketCap":130980172},{"date":"2021-05-28","current":-0.728459,"twenty":-2.655531,"median":-1.567623,"eighty":-1.014684,"marketCap":123338388},{"date":"2021-06-04","current":-0.795167,"twenty":-2.64853,"median":-1.5627,"eighty":-1.010667,"marketCap":134632945},{"date":"2021-06-11","current":-0.94781,"twenty":-2.640264,"median":-1.559356,"eighty":-1.003779,"marketCap":160477457},{"date":"2021-06-18","current":-1.047104,"twenty":-2.607198,"median":-1.555597,"eighty":-1.003779,"marketCap":177289381},{"date":"2021-06-25","current":-1.083211,"twenty":-2.587359,"median":-1.554323,"eighty":-1.003779,"marketCap":183402808},{"date":"2021-07-02","current":-0.992944,"twenty":-2.577755,"median":-1.54827,"eighty":-1.003779,"marketCap":168119241},{"date":"2021-07-08","current":-0.868645,"twenty":-2.571247,"median":-1.543397,"eighty":-1.001923,"marketCap":147073769},{"date":"2021-07-16","current":-0.830462,"twenty":-2.570827,"median":-1.534287,"eighty":-1.001911,"marketCap":140608820},{"date":"2021-07-23","current":-0.837683,"twenty":-2.569976,"median":-1.527184,"eighty":-0.997201,"marketCap":141831505},{"date":"2021-07-30","current":-0.79598,"twenty":-2.566348,"median":-1.527184,"eighty":-0.989357,"marketCap":134770497},{"date":"2021-08-05","current":-0.721238,"twenty":-2.565456,"median":-1.525046,"eighty":-0.985216,"marketCap":122115703},{"date":"2021-08-13","current":-0.777143,"twenty":-2.558807,"median":-1.510765,"eighty":-0.977482,"marketCap":116628902},{"date":"2021-08-20","current":-0.693957,"twenty":-2.535025,"median":-1.509563,"eighty":-0.970593,"marketCap":104144873},{"date":"2021-08-26","current":-0.857569,"twenty":-2.527842,"median":-1.509563,"eighty":-0.967886,"marketCap":128698851},{"date":"2021-09-03","current":-0.906177,"twenty":-2.522882,"median":-1.501822,"eighty":-0.966863,"marketCap":135993649},{"date":"2021-09-10","current":-0.876599,"twenty":-2.521229,"median":-1.500822,"eighty":-0.963107,"marketCap":131554687},{"date":"2021-09-17","current":-0.840815,"twenty":-2.51909,"median":-1.498725,"eighty":-0.951877,"marketCap":126184474},{"date":"2021-09-24","current":-0.807824,"twenty":-2.515298,"median":-1.49021,"eighty":-0.949203,"marketCap":121233324},{"date":"2021-10-01","current":-0.76387,"twenty":-2.512963,"median":-1.485821,"eighty":-0.94602,"marketCap":114636965},{"date":"2021-10-06","current":-0.761491,"twenty":-2.512963,"median":-1.483516,"eighty":-0.944019,"marketCap":114279986},{"date":"2021-10-15","current":-0.741324,"twenty":-2.509639,"median":-1.470856,"eighty":-0.935834,"marketCap":111253421},{"date":"2021-10-22","current":-0.733671,"twenty":-2.500827,"median":-1.466227,"eighty":-0.933578,"marketCap":110104878},{"date":"2021-10-29","current":-0.716089,"twenty":-2.49643,"median":-1.463115,"eighty":-0.930358,"marketCap":107466334},{"date":"2021-11-05","current":-0.739117,"twenty":-2.49147,"median":-1.455373,"eighty":-0.92436,"marketCap":110922261},{"date":"2021-11-12","current":-0.728355,"twenty":-2.482486,"median":-1.447004,"eighty":-0.920137,"marketCap":109307125},{"date":"2021-11-19","current":-0.386369,"twenty":-2.475346,"median":-1.419951,"eighty":-0.911743,"marketCap":75046683},{"date":"2021-11-26","current":-0.368646,"twenty":-2.470234,"median":-1.413372,"eighty":-0.910828,"marketCap":71604324},{"date":"2021-12-03","current":-0.345128,"twenty":-2.465921,"median":-1.409387,"eighty":-0.907248,"marketCap":67036265},{"date":"2021-12-10","current":-0.403167,"twenty":-2.463597,"median":-1.40309,"eighty":-0.905738,"marketCap":78309582},{"date":"2021-12-17","current":-0.313295,"twenty":-2.456306,"median":-1.389572,"eighty":-0.903748,"marketCap":60853071},{"date":"2021-12-23","current":-0.34748,"twenty":-2.450022,"median":-1.381831,"eighty":-0.902029,"marketCap":67493071},{"date":"2021-12-31","current":-0.319174,"twenty":-2.445888,"median":-1.378837,"eighty":-0.897011,"marketCap":61995086},{"date":"2022-01-07","current":-0.336561,"twenty":-2.438566,"median":-1.374379,"eighty":-0.890009,"marketCap":65372187},{"date":"2022-01-14","current":-0.330546,"twenty":-2.435259,"median":-1.374379,"eighty":-0.887406,"marketCap":64203917},{"date":"2022-01-21","current":-0.359744,"twenty":-2.422033,"median":-1.373004,"eighty":-0.88461,"marketCap":69875182},{"date":"2022-01-28","current":-0.344601,"twenty":-2.410537,"median":-1.364205,"eighty":-0.879684,"marketCap":66933925},{"date":"2022-02-04","current":-0.364261,"twenty":-2.408407,"median":-1.361316,"eighty":-0.876997,"marketCap":70752685},{"date":"2022-02-11","current":-0.35121,"twenty":-2.407979,"median":-1.360635,"eighty":-0.873952,"marketCap":68217678},{"date":"2022-02-18","current":-0.3999,"twenty":-2.4055,"median":-1.357152,"eighty":-0.868989,"marketCap":77675059},{"date":"2022-02-25","current":-0.401239,"twenty":-2.4055,"median":-1.354255,"eighty":-0.866236,"marketCap":77935059},{"date":"2022-03-04","current":-0.423267,"twenty":-2.4055,"median":-1.3492,"eighty":-0.857291,"marketCap":82213674},{"date":"2022-03-11","current":-0.320697,"twenty":-2.398887,"median":-1.346995,"eighty":-0.853506,"marketCap":65804496},{"date":"2022-03-18","current":-0.329119,"twenty":-2.397234,"median":-1.344895,"eighty":-0.847851,"marketCap":67532661},{"date":"2022-03-25","current":-0.325812,"twenty":-2.388918,"median":-1.342548,"eighty":-0.840765,"marketCap":66854009},{"date":"2022-04-01","current":-0.301935,"twenty":-2.383963,"median":-1.338645,"eighty":-0.83736,"marketCap":61954723},{"date":"2022-04-08","current":-0.227428,"twenty":-2.374597,"median":-1.333793,"eighty":-0.827311,"marketCap":46666484},{"date":"2022-04-14","current":-0.208602,"twenty":-2.367475,"median":-1.327882,"eighty":-0.818669,"marketCap":42803424},{"date":"2022-04-22","current":-0.177964,"twenty":-2.354249,"median":-1.324122,"eighty":-0.811433,"marketCap":36516842},{"date":"2022-04-29","current":-0.158072,"twenty":-2.337716,"median":-1.320898,"eighty":-0.80387,"marketCap":32435119},{"date":"2022-05-06","current":-0.09804,"twenty":-2.330036,"median":-1.319106,"eighty":-0.796197,"marketCap":20117060},{"date":"2022-05-13","current":-0.079302,"twenty":-2.325012,"median":-1.317041,"eighty":-0.793147,"marketCap":15141105},{"date":"2022-05-20","current":-0.073245,"twenty":-2.319979,"median":-1.316551,"eighty":-0.779563,"marketCap":13984579},{"date":"2022-05-27","current":-0.067867,"twenty":-2.309914,"median":-1.316029,"eighty":-0.776301,"marketCap":12957856},{"date":"2022-06-03","current":-0.067242,"twenty":-2.299849,"median":-1.310904,"eighty":-0.774424,"marketCap":12838360},{"date":"2022-06-10","current":-0.072366,"twenty":-2.291941,"median":-1.307915,"eighty":-0.769174,"marketCap":13816734},{"date":"2022-06-17","current":-0.056191,"twenty":-2.289784,"median":-1.302231,"eighty":-0.761429,"marketCap":10728507},{"date":"2022-06-24","current":-0.062195,"twenty":-2.288346,"median":-1.300568,"eighty":-0.758763,"marketCap":11874923},{"date":"2022-07-01","current":-0.221009,"twenty":-2.282377,"median":-1.299044,"eighty":-0.754436,"marketCap":42197054},{"date":"2022-07-08","current":-0.244479,"twenty":-2.281505,"median":-1.297414,"eighty":-0.747488,"marketCap":46678157},{"date":"2022-07-15","current":-0.209401,"twenty":-2.275405,"median":-1.296606,"eighty":-0.743702,"marketCap":39980638},{"date":"2022-07-22","current":-0.185295,"twenty":-2.264621,"median":-1.294665,"eighty":-0.739566,"marketCap":35378254},{"date":"2022-07-29","current":-0.137119,"twenty":-2.253837,"median":-1.292774,"eighty":-0.734705,"marketCap":26179907},{"date":"2022-08-05","current":-0.166395,"twenty":-2.250243,"median":-1.289012,"eighty":-0.728459,"marketCap":31769672}],"updateTime":1747636216283}}}